GlassScriptPhysician profile
William Tyler Stone
NPI 1023322039
$13,539.96
in general payments reported to CMS, 2019-2025
48 companies · $3,952 in 2025
The $3,952 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,349 · 2024: $7,239 · 2025: $3,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $784 · Education: $4.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,751.75 |
| Travel and Lodging | $783.56 |
| Education | $4.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,591.58 | 2023-2025 | Qulipta, Ubrelvy, Botox |
| Inspire Medical Systems, INC. | $1,457.01 | 2024-2025 | Inspire |
| Tg Therapeutics, INC. | $1,331.87 | 2023-2025 | |
| Ucb, INC. | $1,158.83 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Pfizer INC. | $1,086.58 | 2023-2025 | |
| Biogen, INC. | $730.84 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Argenx US, INC. | $586.87 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $557.59 | 2024-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $474.20 | 2023-2025 | |
| Sk Life Science, INC. | $426.95 | 2023-2025 | Xcopri |
| Abbott Laboratories | $356.38 | 2024-2025 | Infinity |
| Alexion Pharmaceuticals, INC. | $341.37 | 2023-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $335.84 | 2023-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $276.80 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $238.33 | 2024-2025 | Daybue, Nuplazid |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $216.71 | 2024-2025 | Amyvid, Kisunla, Reyvow |
| Neurocrine Biosciences, INC. | $196.98 | 2023-2025 | Ingrezza, Ongentys |
| Mallinckrodt Hospital Products INC. | $185.51 | 2023-2024 | Acthar |
| Livanova USA, INC. | $173.23 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $158.83 | 2024-2025 | Uplizna |
| Axsome Therapeutics, INC. | $123.55 | 2025 | Symbravo |
| Catalyst Pharmaceuticals, INC. | $115.83 | 2023-2025 | Firdapse |
| Otsuka America Pharmaceutical, INC. | $111.18 | 2024-2025 | Rexulti |
| Celgene Corporation | $110.42 | 2023-2025 | Zeposia |
| Eisai INC. | $108.19 | 2023-2025 | |
| Neurelis, INC. | $100.63 | 2023-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $94.35 | 2023-2024 | Rytary, Lyvispah |
| Astrazeneca Pharmaceuticals LP | $88.89 | 2024-2025 | Wainua |
| Vanda Pharmaceuticals INC. | $83.84 | 2024-2025 | Ponvory |
| Ani Pharmaceuticals, INC. | $75.78 | 2025 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $66.89 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $65.97 | 2023-2024 | Amvuttra |
| Merz Pharmaceuticals, LLC | $59.68 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Harmony Biosciences LLC | $47.60 | 2024-2025 | |
| Medtronic, INC. | $47.19 | 2024-2025 | Percept PC Brainsense |
| Cycle Pharmaceuticals INC | $43.34 | 2025 | Tascenso Odt |
| Jazz Pharmaceuticals INC. | $42.96 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $35.43 | 2024 | Austedo Xr, Ajovy |
| Tanabe Pharma America, INC. | $32.57 | 2024 | |
| Scilex Pharmaceuticals INC. | $32.55 | 2024 | |
| Csl Behring | $27.79 | 2024 | Hizentra |
| Kyowa Kirin, INC. | $26.10 | 2023 | Nourianz |
| Sumitomo Pharma America, INC. | $23.51 | 2023 | Aptiom |
| Springworks Therapeutics, INC. | $23.15 | 2025 | Gomekli |
| Horizon Therapeutics Plc | $21.49 | 2023 | Uplizna |
| Octapharma USA, INC. | $17.14 | 2023 | Panzyga |
| Grifols USA, LLC | $17.10 | 2025 | Gamunex-C |
| Banner Life Sciences, LLC | $14.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.